UPDATE: SunTrust Robinson Humphrey Starts uniQure BV (QURE) at Buy

(updated to add analyst comment)

SunTrust Robinson Humphrey initiates coverage on uniQure BV (NASDAQ: QURE) with a Buy rating and a price target of $48.00.

Analyst Ed Nash comments "We believe Novartis’ $8.7 billion acquisition of AveXis is a strong endorsement for uniQure. We believe uniQure possesses the qualities of an ideal gene therapy M&A target. We believe strong fits with uniQure would be companies with an established presence and strategic interest in Hemophilia."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $32.86 yesterday.

You May Also Be Interested In

• Raymond James Starts Capital Bancorp (CBNK) at Market Perform
• CLSA Upgrades Taiyo Yuden Co Ltd (6976:JP) (TYOYY) to High-Conviction Outperform (1)
• JPMorgan Downgrades Inpex Corp (1605:JP) to Neutral